BR112021013976A2 - Método para produção e uso de uma forma de dosagem de melatonina, e composição de melatonina micronizada sólida - Google Patents

Método para produção e uso de uma forma de dosagem de melatonina, e composição de melatonina micronizada sólida Download PDF

Info

Publication number
BR112021013976A2
BR112021013976A2 BR112021013976-1A BR112021013976A BR112021013976A2 BR 112021013976 A2 BR112021013976 A2 BR 112021013976A2 BR 112021013976 A BR112021013976 A BR 112021013976A BR 112021013976 A2 BR112021013976 A2 BR 112021013976A2
Authority
BR
Brazil
Prior art keywords
melatonin
dosage form
carboxylic acid
hydrogel
powder
Prior art date
Application number
BR112021013976-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Syed M. Shah
Daniel Hassan
Original Assignee
Société des Produits Nestlé S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Société des Produits Nestlé S.A. filed Critical Société des Produits Nestlé S.A.
Publication of BR112021013976A2 publication Critical patent/BR112021013976A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112021013976-1A 2019-01-18 2020-01-17 Método para produção e uso de uma forma de dosagem de melatonina, e composição de melatonina micronizada sólida BR112021013976A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962794159P 2019-01-18 2019-01-18
US62/794,159 2019-01-18
PCT/US2020/014086 WO2020150605A1 (en) 2019-01-18 2020-01-17 Solid micronized melatonin composition

Publications (1)

Publication Number Publication Date
BR112021013976A2 true BR112021013976A2 (pt) 2021-09-21

Family

ID=71610353

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021013976-1A BR112021013976A2 (pt) 2019-01-18 2020-01-17 Método para produção e uso de uma forma de dosagem de melatonina, e composição de melatonina micronizada sólida

Country Status (9)

Country Link
US (2) US20200230059A1 (https=)
EP (1) EP3911315A4 (https=)
JP (1) JP2022534159A (https=)
CN (1) CN113490491A (https=)
AU (1) AU2020209940A1 (https=)
BR (1) BR112021013976A2 (https=)
CA (1) CA3126413A1 (https=)
MX (1) MX2021008623A (https=)
WO (1) WO2020150605A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022012199A2 (pt) * 2020-01-17 2022-09-13 Nestle Sa Forma de dosagem com péletes de melatonina de liberação sustentada
AU2022242966A1 (en) * 2021-03-22 2023-10-05 Fertis India Pvt. Ltd. Agricultural composition comprising melatonin and carboxylic compounds for enhancing antioxidant property to increase crop yield
CA3221463A1 (en) * 2021-06-09 2022-12-15 Agb-Pharma Ab Melatonin formulation in solid dosage form
CA3268494A1 (en) 2022-10-14 2024-04-18 Société des Produits Nestlé S.A. DELAYED-RELEASE MELATONIN COMPOSITIONS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9532952B2 (en) * 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
US8691275B2 (en) * 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
DK2949322T3 (en) * 2014-05-28 2018-07-23 Valpharma S P A FORMULATION FOR ORAL ADMINISTRATION COMPREHENSIVE MELATONIN IN STABLE FORM AND PROCEDURE FOR PREPARING THEREOF
ES2684414B1 (es) * 2017-03-31 2019-12-11 Laboratorios Vinas S A Composición galénica, para uso oral, que comprende melatonina micronizada y una sal de zinc y método y uso correspondientes

Also Published As

Publication number Publication date
JP2022534159A (ja) 2022-07-28
EP3911315A4 (en) 2022-10-12
MX2021008623A (es) 2021-08-19
EP3911315A1 (en) 2021-11-24
US20220079921A1 (en) 2022-03-17
CN113490491A (zh) 2021-10-08
WO2020150605A1 (en) 2020-07-23
CA3126413A1 (en) 2020-07-23
AU2020209940A1 (en) 2021-07-22
US20200230059A1 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
CN102724970B (zh) 来那替尼马来酸盐的片剂制剂
BR112021013976A2 (pt) Método para produção e uso de uma forma de dosagem de melatonina, e composição de melatonina micronizada sólida
CN103402497A (zh) 快速分散颗粒、口腔崩解片以及方法
US11559485B2 (en) Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
US20230355620A1 (en) Amorphous solid dispersions of dasatinib and uses thereof
JP2001517616A (ja) 活性成分としてクロドロン酸塩および賦形剤としてケイ化微晶質セルロースを含む医薬製剤
BRPI0415953B1 (pt) formulação de dosagem de liberação controlada e conjunto de formas de dosagem de liberação controlada
WO2008064202A2 (en) Modified-release formulations of calcium receptor-active compounds
CN103393623A (zh) 新型制剂
US20160030357A1 (en) Composition for manufacturing orally disintegrating dosage form to protect coating layer of active substance
US20250025463A1 (en) Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib and in vitro characterization thereof
AU2021207284B2 (en) Dosage form with sustained release melatonin pellets
JP2022084795A (ja) 医薬組成物
CN119055604A (zh) 含有对乙酰氨基酚和布洛芬的药物组合物
CN103040798A (zh) 一种苯扎贝特缓释药物组合物
WO2006003587A2 (en) Solid oral dosage forms of azabicyclo derivatives
JP2025526729A (ja) ナポラフェニブを含む非晶質固体分散体
EP3673901A1 (en) Pharmaceutical composition particles, orally disintegrating preparation containing same, and method for producing pharmaceutical composition particles
CN119365195A (zh) 含有匹米替比的医药组合物
HK40113021A (zh) 含有对乙醯氨基酚和布洛芬的药物组合物
JPWO1997033571A1 (ja) エカドトリルの速放微分散性製剤
TW201609197A (zh) 每日一次投藥之提供藥學及臨床效果之莫沙必利持續釋放製劑

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements